Oarsman Capital’s West Pharmaceutical WST Stock Holding History

Oarsman Capital’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-478	Closed	-$157K	–	862
2024 Q4	$157K	Buy	478 +110	+30%	+$34.6K	0.03%	265
2024 Q3	$110K	Buy	+368	New	+$113K	0.02%	323

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DCP

Durable Capital Partners Bethesda, Maryland $9.71B AUM 26.27% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Oarsman Capital's WST Position: Q1 2025 in Review

Oarsman Capital sold out of West Pharmaceutical (WST) in Q1 2025, closing a stake of 478 shares — an estimated $157K sold.

Oarsman Capital first reported a position in WST in Q3 2024 and held it in 2 quarters. The position peaked at $157K in Q4 2024. 713 funds tracked by Wall St. Rank hold WST as of Q1 2025.

Oarsman Capital reported no remaining West Pharmaceutical position as of Q1 2025 after selling out during the quarter.
Oarsman Capital sold 478 West Pharmaceutical shares in Q1 2025, an estimated $157K.
Oarsman Capital first reported a position in West Pharmaceutical in Q3 2024 and held it in 2 quarters.
Oarsman Capital's West Pharmaceutical position peaked at $157K in Q4 2024.
713 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2025.

Based on Oarsman Capital's 13F filing for Q1 2025, filed 14 May 2025.